



HHS Public Access

Author manuscript

JAMA Psychiatry. Author manuscript; available in PMC 2018 January 26.

Published in final edited form as:

JAMA Psychiatry. 2016 May 01; 73(5): 497–505. doi:10.1001/jamapsychiatry.2016.0129.

Correspondence: S Hong Lee, The University of New England, Armidale, NSW 2351, Australia, hong.lee@une.edu.au, tel +61 2 6773 3665, fax +61 2 6773 3275.

Consortium authors

Ole A Andreassen, MD,PhD^{1,2}; Elvira Bramon, MD,PhD³; Richard Bruggeman, MD,PhD⁴; Murray J Cairns, PhD^{5,6,7}; Rita M Cantor, PhD⁸; C Robert Cloninger, MD, PhD⁹; David Cohen, MD, PhD¹⁰; Benedicto Crespo-Facorro, MD, PhD^{11,12}; Ariel Darvasi, PhD¹³; Lynn E DeLisi, MD^{14,15}; Timothy Dinan, MD,PhD¹⁶; Srdjan Djurovic, PhD^{17,18}; Gary Donohoe, PhD^{19,20}; Elodie Drapeau, PhD²¹; Valentina Escott-Price, PhD²²; Nelson B Freimer, MD²³; Lyudmila Georgieva, PhD²²; Lieuwe de Haan, MD,PhD²⁴; Frans A Henskens, BMath,DipEd,DipCompSc,PhD^{5,25,26}; Inge Joa, PhD²⁷; Antonio Julià, PhD²⁸; Andrey Khrunin, PhD²⁹; Bernard Lerer, MD³⁰; Svetlana Limborska, PhD²⁹; Carmel M Loughland, BA(Hons), PhD^{5,6}; Milan Macek Jr, MD,PhD³¹; Patrik KE Magnusson, PhD³²; Sara Marsal, MD,PhD²⁸; Robert W McCarley, MD^{14,15}; Andrew M McIntosh, MD,FRCPsych^{33,34}; Andrew McQuillin, PhD³⁵; Bela Melegh, MD,PhD,DSc^{36,37}; Patricia T Michie, PhD^{38,39}; Derek W Morris, PhD^{19,20}; Kieran C Murphy, MD,PhD⁴⁰; Inez Myin-Germeys, PhD⁴¹; Ann Olincy, MD⁴²; Jim Van Os, MD,PhD^{43,44}; Christos Pantelis, MD, Hon MD (Athens), MRCPsych, FRANZCP^{5,45}; Danielle Posthuma, PhD^{46,47,48}; Digby Quedest, MBChB,MD,FRCPsych⁴⁹; Ulrich Schall, MD,FRANZCP,PhD,DSc^{5,6}; Rodney J Scott, PhD,FRCPath,FHGSA,FFSc^{5,7,50}; Larry J Seidman, PhD^{15,51}; Draga Toncheva, MD,PhD,DSc⁵²; Paul A Tooney, PhD^{5,7,53}; John Waddington, PhD,DSc⁵⁴; Daniel R Weinberger, MD^{55,56}; Mark Weiser, MD⁵⁷; Jing Qin Wu, PhD^{7,58}

¹ NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, 0424 Oslo, Norway ² Division of Mental Health and Addiction, Oslo University Hospital, 0424 Oslo, Norway ³ University College London, London WC1E 6BT, UK ⁴ University Medical Center Groningen, Department of Psychiatry, University of Groningen, NL-9700 RB, The Netherlands ⁵ Schizophrenia Research Institute, Sydney NSW 2010, Australia ⁶ Priority Centre for Translational Neuroscience and Mental Health, University of Newcastle, Newcastle NSW 2300, Australia ⁷ School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan NSW 2308, Australia ⁸ Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA ⁹ Department of Psychiatry, Washington University, St. Louis, Missouri 63110, USA ¹⁰ Department of Child and Adolescent Psychiatry, Assistance Publique Hôpitaux de Paris, Pierre and Marie Curie University, and Institute for Intelligent Systems and Robotics, Paris, 75013 ¹¹ CIBERSAM, University Hospital Marqués de Valdecilla, University of Cantabria - IDIVAL, Department of Psychiatry, Santander, Spain ¹² Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain ¹³ Department of Genetics, The Hebrew University of Jerusalem, 91905 Jerusalem, Israel ¹⁴ VA Boston Health Care System, Brockton, Massachusetts 02301, USA ¹⁵ Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, USA ¹⁶ Department of Psychiatry, University College Cork, Co. Cork, Ireland ¹⁷ NORMENT, KG Jebsen Centre for Psychosis Research, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway ¹⁸ Department of Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway ¹⁹ Cognitive Genetics and Therapy Group, School of Psychology and Discipline of Biochemistry, National University of Ireland Galway, Co. Galway, Ireland ²⁰ Neuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity College Dublin, Dublin 8, Ireland ²¹ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA ²² MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK ²³ Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California 90095, USA ²⁴ Academic Medical Centre University of Amsterdam, Department of Psychiatry, 1105 AZ Amsterdam, The Netherlands ²⁵ School of Electrical Engineering and Computer Science, University of Newcastle, Newcastle NSW 2308, Australia ²⁶ Priority Research Centre for Health Behaviour, University of Newcastle, Newcastle NSW 2308, Australia ²⁷ Regional Centre for Clinical Research in Psychosis, Department of Psychiatry, Stavanger University Hospital, 4011 Stavanger, Norway ²⁸ Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 08035, Spain ²⁹ Institute of Molecular Genetics, Russian Academy of Sciences, Moscow 123182, Russia ³⁰ Department of Psychiatry, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel ³¹ Department of Biology and Medical Genetics, 2nd Faculty of Medicine and University Hospital Motol, 150 06, Prague, Czech Republic ³² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm SE-17177, Sweden ³³ Division of Psychiatry, University of Edinburgh, Edinburgh EH16 4SB, UK ³⁴ Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh EH16 4SB, UK ³⁵ Molecular Psychiatry Laboratory, Division of Psychiatry, University College London, London WC1E 6JJ, UK ³⁶ Department of Medical Genetics, University of Pécs, Pécs H-7624, Hungary ³⁷ Szentagothai Research Center, University of Pécs, Pécs H-7624, Hungary ³⁸ School of Psychology, University of Newcastle, Newcastle NSW 2308, Australia ³⁹ Schizophrenia Research Institute, Sydney NSW 2031, Australia ⁴⁰ Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin 2, Ireland ⁴¹ Center for Contextual Psychiatry, Dept of Neuroscience, KU Leuven, 3000 Leuven, Belgium ⁴² Department of Psychiatry, University of Colorado Denver, Aurora, Colorado 80045, USA ⁴³ Institute of Psychiatry, King's College London, London SE5 8AF, UK ⁴⁴ Maastricht University Medical Centre, South Limburg Mental Health Research and Teaching Network, EURON, 6229 HX Maastricht, The Netherlands ⁴⁵ Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne & Melbourne Health, Melbourne VIC 3053, Australia ⁴⁶ Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University, Amsterdam 1081, The Netherlands ⁴⁷ Department of Complex Trait Genetics, Neuroscience Campus Amsterdam, VU University Medical Center Amsterdam, Amsterdam 1081, The Netherlands ⁴⁸ Department of Child and Adolescent Psychiatry, Erasmus University Medical Center, Rotterdam 3000, The Netherlands ⁴⁹ Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK ⁵⁰ Hunter New England Health Service, Newcastle NSW 2308, Australia ⁵¹ Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston, Massachusetts 02114, USA ⁵² Department of Medical Genetics, Medical University, Sofia1431, Bulgaria ⁵³ Priority Research Centre for Translational Neuroscience and Mental Health, University of Newcastle, Newcastle NSW 2300, Australia ⁵⁴ Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland ⁵⁵ Lieber Institute for Brain Development, Baltimore, Maryland 21205, USA ⁵⁶ Departments of Psychiatry, Neurology, Neuroscience and Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA ⁵⁷ Sheba Medical Center, Tel Hashomer 52621, Israel ⁵⁸ Schizophrenia Research Institute, Sydney NSW 2010, Australia.

Consortium collaborators

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Evidence for genetic overlap between schizophrenia and age at

Rolf Adolfsson, MD, PhD¹; Ingrid Agartz, MD, PhD^{2,3,4}; Margot Albus, MD⁵; Madeline Alexander, PhD⁶; Farooq Amin, MD^{7,8}; Silviu A Bacanu, PhD⁹; Martin Begemann, MD¹⁰; Richard A Belliveau Jr, BA¹¹; Judit Bene, PhD^{12,13}; Sarah E Bergen, PhD^{11,14}; Elizabeth Bevilacqua, BS¹¹; Tim B Bigdeli, PhD⁹; Donald W Black, MD¹⁵; Douglas HR Blackwood, PhD, FRCPsych¹⁶; Anders D Borglum, MD, PhD^{17,18,19,20}; Nancy G Buccola, APRN, BC²¹; Randy L Buckner, PhD^{22,23,24}; Joseph D Buxbaum, PhD^{25,26,27,28}; William Byerley, MD²⁹; Wiepke Cahn, MD, PhD³⁰; Guiqing Cai, MD^{25,26}; Dominique Campion, MD, PhD³¹; Vaughan J Carr, MD, FRANZCP, FRCP^{32,33}; Noa Carrera, PhD³⁴; Stanley V Catts, MD, FRANZCP^{32,35}; Kimberley D Chambert, MSc¹; David St Clair, MD, PhD³⁶; Paul Cormican, PhD³⁷; Aiden Corvin, MD, PhD³⁷; Nick Craddock, MD, PhD^{34,38}; James J Crowley, PhD³⁹; David Curtis, MD, PhD, MRCPsych^{40,41}; Michael Davidson, MD⁴²; Kenneth L Davis, MD²⁵; Ditte Demontis, MSc, PhD^{17,18,20}; Dimitris Dikeos, MD⁴³; Jubao Duan, PhD^{44,45}; Frank Dudbridge, PhD⁴⁶; Hannelore Ehrenreich, MD, DVM¹⁰; Peter Eichhammer, MD, PhD⁴⁷; Tônu Esko, PhD^{48,49,50,51}; Ayman H Fanous, MD^{52,53,54,55}; Jürgen Del Favero, PhD⁵⁶; Marta di Forti, MBBS, MRCPsych, PhD⁵⁷; Robert Freedman, MD⁵⁸; Marion Friedl, PhD⁵⁹; Joseph I Friedman, MD²⁵; Menachem Fromer, PhD^{11,60,61,62}; Pablo V Gejman, MD^{44,63}; Giulio Genovese, PhD¹¹; Elliot S Gershon, MD⁶⁴; Ina Giegling, PhD^{59,65}; Michael Gill, MRCPsych, MD³⁷; Stephanie Godard, MS⁶⁶; Jacob Gratten, PhD⁶⁷; Jakob Grove, MSc, PhD^{17,18,20}; Hugh Gurling, MPhil, MD, FRCPsych⁴¹; Mei-Hua Hall, PhD⁶⁸; Christian Hammer, PhD¹⁰; Marian L Hamshere, PhD³⁴; Mark Hansen, PhD⁶⁹; Thomas Hansen, MSc, PhD^{70,71}; Vahram Haroutunian, PhD^{25,28,72}; Annette M Hartmann, PhD⁵⁹; Peter A Holmans, PhD^{34,38}; David M Hougaard, MD⁷³; Christina M Hultman, PhD¹⁴; Assen V Jablensky, MD, DMSc, FRANZCP, FRCPsych^{32,74,75,76}; Erik G Jönsson, MD, PhD^{2,77}; Anna K Kähler, PhD¹⁴; René S Kahn, MD, PhD³⁰; Luba Kalaydjieva, MD, PhD^{78,79}; Sena Karachanak-Yankova, PhD⁸⁰; David Kavanagh, PhD³⁴; Matthew C Keller, PhD⁸¹; Brian J Kelly, PhD, FRANZCP⁸²; Kenneth S Kendler, MD⁸³; George Kirov, MD, PhD³⁴; Janis Klovins, PhD⁸⁴; James A Knowles, MD, PhD⁸⁵; Bettina Konte, MSc⁵⁹; Eugenia Kravariti, PhD⁵⁷; Vaidutis Kucinskis, PhD⁸⁶; Zita Ausrele Kucinskiene, MD, PhD⁸⁶; Hana Kuzelova-Ptackova, PhD⁸⁷; Claudine Laurent, MD, PhD^{6,88}; Sophie E Legge, BSc³⁴; Todd Lencz, PhD^{89,90,91}; Douglas F Levinson, MD⁶; Kung-Yee Liang, PhD⁹²; Jeffrey Lieberman, MD⁹³; Jan Lubinski, MD, PhD⁹⁴; Brion S Maher, PhD⁹⁵; Wolfgang Maier, MD⁹⁶; Anil K Malhotra, MD^{89,90,91}; Jacques Mallet, PhD⁹⁷; Morten Mattingsdal, MS^{2,98}; Steven A McCarroll, PhD^{11,50}; Colm McDonald, MD, PhD⁹⁹; Carin J Meijer, PhD¹⁰⁰; Ingrid Melle, MD, PhD^{2,101}; Raquella I Meshulam-Gately, PhD^{102,103}; Andres Metspalu, MD, PhD⁴⁸; Lili Milani, PhD⁴⁸; Vihra Milanova, MD, PhD¹⁰⁴; Jennifer L Moran, PhD¹¹; Ole Mors, MD, PhD^{18,20,105}; Preben B Mortensen, MD, DMSc^{18,20,106}; Bryan J Mowry, MB, BS, MD, FRANZCP^{107,108}; Robin M Murray, FRS⁵⁷; Mari Nelis, PhD⁴⁸; Deborah A Nertney, BSc¹⁰⁸; Gerald Nestadt, MBChB MPH¹⁰⁹; Liene Nikitina-Zake, MD, PhD⁸⁴; Annelie Nordin, ¹; Eadbhard O'Callaghan, MD, DSc, FRCPsych¹¹⁰; Michael C O'Donovan, MD, PhD^{34,38}; F Anthony O'Neill, MD, PhD¹¹¹; Sang-Yun Oh, PhD¹¹²; Line Olsen, MSc, PhD^{70,71}; Roel A Ophoff, PhD^{30,113,114}; Michael J Owen, MD, PhD^{34,38}; Aarno Palotie, MD, PhD^{11,61,115}; George N Papadimitriou, MD⁴³; Sergi Papiol, PhD¹⁰; Elena Parkhomenko, PhD²⁵; Carlos N Pato, MD, PhD⁸⁵; Michele T Pato, MD, PhD⁸⁵; Diana O Perkins, MD, MPH¹¹⁶; Tracey L Petryshen, PhD^{11,103,117}; Marco Picchioni, MBBS, MRCPsych, PhD⁵⁷; Jonathan Pimm, MB, BS, MD, MRCPsych⁴¹; Andrew J Pocklington, PhD³⁴; John Powell, PhD⁵⁷; Ann E Pulver, PhD¹⁰⁹; Henrik B Rasmussen, DVM, PhD^{70,71}; Abraham Reichenberg, PhD²⁵; Mark A Reimers, PhD¹¹⁸; Alexander L Richards, PhD^{34,38}; Brien P Riley, PhD⁸³; Joshua L Roffman, MD, MMSc^{23,24}; Panos Roussos, MD, PhD^{60,119}; Dan Rujescu, MD, PhD^{59,65}; Alan R Sanders, MD, PhD^{44,63}; Christian R Schubert, PhD¹²⁰; Sibylle G Schwab, PhD¹²¹; Edward W Scolnick, MD¹¹; Jianxin Shi, PhD¹²²; Jeremy M Silverman, PhD^{25,123}; Pamela Sklar, MD, PhD^{28,60,119}; Petr Slominsky, PhD¹²⁴; Jordan W Smoller, MD, ScD^{11,61}; Erik Söderman, PhD⁷⁷; Chris C A Spencer, PhD¹²⁵; Eli A Stahl, PhD^{51,60}; Elisabeth Stogmann, MD¹²⁶; Richard E Straub, PhD¹²⁷; Eric Strengman, BSc^{30,128}; T Scott Stroup, MD, MPH⁹³; Patrick F Sullivan, MD, FRANZCP^{14,39,116}; Dragan M Svrakic, MD, PhD¹²⁹; Jin P Szatkiewicz, PhD³⁹; Srinivas Thirumalai, MB, BS, MD, MRCPsych¹³⁰; Timothea Touloupoulou, PhD¹³¹; Dermot Walsh, MD¹³²; James TR Walters, MD, PhD³⁴; Bradley T Webb, PhD⁹; Jens R Wendland, MD¹²⁰; Thomas Werge, MSc, PhD^{70,71,133}; Dieter B Wildenauer, PhD¹³⁴; Nigel M Williams, PhD³⁴; Stephanie Williams, ScM³⁹; Aaron R Wolen, PhD¹¹⁸; Brandon K Wormley, BA⁹; Hualin Simon Xi, PhD¹³⁵; Fritz Zimprich, MD, PhD¹²⁶

¹ Department of Clinical Sciences, Psychiatry, Umeå University, SE-901 87 Umeå, Sweden ² NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, 0424 Oslo, Norway ³ Department of Psychiatry, Diakonhjemmet Hospital, 0319 Oslo, Norway ⁴ Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, SE-17176 Stockholm, Sweden ⁵ State Mental Hospital, 85540 Haar, Germany ⁶ Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California 94305, USA ⁷ Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia 30322, USA ⁸ Department of Psychiatry and Behavioral Sciences, Atlanta Veterans Affairs Medical Center, Atlanta, Georgia 30033, USA ⁹ Virginia Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia 23298, USA ¹⁰ Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen 37075, Germany ¹¹ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA ¹² Department of Medical Genetics, University of Pécs, Pécs H-7624, Hungary ¹³ Szentagothai Research Center, University of Pécs, Pécs H-7624, Hungary ¹⁴ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm SE-17177, Sweden ¹⁵ Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, USA ¹⁶ Division of Psychiatry, University of Edinburgh, Edinburgh EH16 4SB, UK ¹⁷ Department of Biomedicine, Aarhus University ¹⁸ Centre for Integrative Sequencing, iSEQ, Aarhus University ¹⁹ Aarhus University Hospital, Risskov ²⁰ The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH. ²¹ School of Nursing, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA ²² Center for Brain Science, Harvard University, Cambridge, Massachusetts 02138, USA ²³ Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA ²⁴ Athinoula A. Martinos Center, Massachusetts General Hospital, Boston, Massachusetts 02129, USA ²⁵ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA ²⁶ Department of Human Genetics, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA ²⁷ Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA ²⁸ Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA ²⁹ Department of Psychiatry,

first birth in women

University of California at San Francisco, San Francisco, California, 94143 USA³⁰ University Medical Center Utrecht, Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, 3584 Utrecht, The Netherlands³¹ Centre Hospitalier du Rouvray and INSERM U1079 Faculty of Medicine, 76301 Rouen, France³² Schizophrenia Research Institute, Sydney NSW 2010, Australia³³ School of Psychiatry, University of New South Wales, Sydney NSW 2031, Australia³⁴ MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK³⁵ Royal Brisbane and Women's Hospital, University of Queensland, Brisbane QLD 4072, Australia³⁶ University of Aberdeen, Institute of Medical Sciences, Aberdeen, AB25 2ZD, UK³⁷ Neuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity College Dublin, Dublin 8, Ireland³⁸ National Centre for Mental Health, Cardiff University, Cardiff, CF24 4HQ, UK³⁹ Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599-7264, USA⁴⁰ Department of Psychological Medicine, Queen Mary University of London, London E1 1BB, UK⁴¹ Molecular Psychiatry Laboratory, Division of Psychiatry, University College London, London WC1E 6JJ, UK⁴² Sheba Medical Center, Tel Hashomer 52621, Israel⁴³ First Department of Psychiatry, University of Athens Medical School, Athens 11528, Greece⁴⁴ Department of Psychiatry and Behavioral Sciences, NorthShore University HealthSystem, Evanston, Illinois 60201, USA⁴⁵ Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois 60637, USA⁴⁶ Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK⁴⁷ Department of Psychiatry, University of Regensburg, 93053 Regensburg, Germany⁴⁸ Estonian Genome Center, University of Tartu, Tartu 50090, Estonia⁴⁹ Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children's Hospital, Boston, Massachusetts 02115, USA⁵⁰ Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA⁵¹ Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA⁵² Mental Health Service Line, Washington VA Medical Center, Washington DC 20422, USA⁵³ Department of Psychiatry, Georgetown University School of Medicine, Washington DC 20057, USA⁵⁴ Department of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23298, USA⁵⁵ Department of Psychiatry, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA⁵⁶ Applied Molecular Genomics Unit, VIB Department of Molecular Genetics, University of Antwerp, B-2610 Antwerp, Belgium⁵⁷ King's College London, London SE5 8AF, UK⁵⁸ Department of Psychiatry, University of Colorado Denver, Aurora, Colorado 80045, USA⁵⁹ Department of Psychiatry, University of Halle, 06112 Halle, Germany⁶⁰ Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA⁶¹ Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA⁶² Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA⁶³ Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois 60637, USA⁶⁴ Departments of Psychiatry and Human Genetics, University of Chicago, Chicago, Illinois 60637 USA⁶⁵ Department of Psychiatry, University of Munich, 80336, Munich, Germany⁶⁶ Departments of Psychiatry and Human and Molecular Genetics, INSERM, Institut de Myologie, Hôpital de la Pitié-Salpêtrière, Paris, 75013, France⁶⁷ Queensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia⁶⁸ Mclean Hospital, Harvard Medical School, 115 Mill St, Belmont MA 02478, USA⁶⁹ Illumina, La Jolla, California, California 92122, USA⁷⁰ Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, Mental Health Services Copenhagen, DK-4000, Denmark⁷¹ The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark⁷² J.J. Peters VA Medical Center, Bronx, New York, New York 10468, USA⁷³ Section of Neonatal Screening and Hormones, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, DK-2300, Denmark⁷⁴ School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Perth, WA 6009, Australia⁷⁵ Centre for Clinical Research in Neuropsychiatry, School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Medical Research Foundation Building, Perth WA 6000, Australia⁷⁶ The Perkins Institute for Medical Research, The University of Western Australia, Perth, WA 6009, Australia⁷⁷ Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, SE-17176 Stockholm, Sweden⁷⁸ Centre for Medical Research, The University of Western Australia, Perth, WA 6009, Australia⁷⁹ The Perkins Institute for Medical Research, The University of Western Australia, Perth, WA 6009, Australia⁸⁰ Department of Medical Genetics, Medical University, Sofia 1431, Bulgaria⁸¹ Department of Psychology, University of Colorado Boulder, Boulder, Colorado 80309, USA⁸² Priority Centre for Translational Neuroscience and Mental Health, University of Newcastle, Newcastle NSW 2300, Australia⁸³ Virginia Institute for Psychiatric and Behavioral Genetics, Departments of Psychiatry and Human and Molecular Genetics, Virginia Commonwealth University, Richmond, Virginia 23298, USA⁸⁴ Latvian Biomedical Research and Study Centre, Riga, LV-1067, Latvia⁸⁵ Department of Psychiatry and Zilkha Neurogenetics Institute, Keck School of Medicine at University of Southern California, Los Angeles, California 90089, USA⁸⁶ Faculty of Medicine, Vilnius University, LT-01513 Vilnius, Lithuania⁸⁷ Department of Biology and Medical Genetics, 2nd Faculty of Medicine and University Hospital Motol, 150 06 Prague, Czech Republic⁸⁸ Department of Child and Adolescent Psychiatry, Pierre and Marie Curie Faculty of Medicine, Paris 75013, France⁸⁹ The Zucker Hillside Hospital, Glen Oaks, New York 11004, USA⁹⁰ The Feinstein Institute for Medical Research, Manhasset, New York 11030, USA⁹¹ The Hofstra NS-LIJ School of Medicine, Hempstead, New York 11549, USA⁹² Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA⁹³ Department of Psychiatry, Columbia University, New York, New York 10032, USA⁹⁴ Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, 70-453 Szczecin, Poland⁹⁵ Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA⁹⁶ Department of Psychiatry, University of Bonn, D-53127 Bonn, Germany⁹⁷ Centre National de la Recherche Scientifique, Laboratoire de Génétique Moléculaire de la Neurotransmission et des Processus Neurodégénératifs, Hôpital de la Pitié Salpêtrière, 75013, Paris, France⁹⁸ Research Unit, Sørlandet Hospital, 4604 Kristiansand, Norway⁹⁹ Department of Psychiatry, National University of Ireland Galway, Co. Galway, Ireland¹⁰⁰ Academic Medical Centre University of Amsterdam, Department of Psychiatry, 1105 AZ Amsterdam, The Netherlands¹⁰¹ Division of Mental Health and Addiction, Oslo University Hospital, 0424 Oslo, Norway¹⁰² Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston, Massachusetts 02114, USA¹⁰³ Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, USA¹⁰⁴ First Psychiatric Clinic, Medical University, Sofia 1431, Bulgaria¹⁰⁵ Aarhus University Hospital, Risskov¹⁰⁶

Divya Mehta, PhD¹, Felix C Tropf, PhD², Jacob Gratten, PhD¹, Andrew Bakshi, MSc¹, Zhihong Zhu, PhD¹, Silviu-Alin Bacanu, PhD^{3,4}, Gibran Hemani, PhD⁵, Patrik KE Magnusson, PhD⁶, Nicola Barban, PhD⁷, Tõnu Esko, PhD⁸, Andres Metspalu, MD⁸, Harold Snieder, PhD⁹, Bryan J Mowry, MD^{1,10}, Kenneth S Kendler, MD^{3,4,11}, Jian Yang, PhD¹, Peter M Visscher, PhD¹, John J McGrath, MD¹, Melinda C Mills, PhD⁷, Naomi R Wray, PhD¹, S Hong Lee, PhD^{1,12}, Schizophrenia Working Group of the Psychiatric Genomics Consortium¹³, LifeLines Cohort Study¹⁴, and TwinsUK

National Centre for Register-based Research, and Centre for Integrative Sequencing, iSEQ, Aarhus University¹⁰⁷ Queensland Brain Institute, The University of Queensland, Brisbane QLD 4072, Australia¹⁰⁸ Queensland Centre for Mental Health Research, University of Queensland, Brisbane QLD 4076, Australia¹⁰⁹ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA¹¹⁰ DETECT Early Intervention Service for Psychosis, Blackrock, Co. Dublin, Ireland¹¹¹ Centre for Public Health, Institute of Clinical Sciences, Queen's University Belfast, Belfast BT12 6AB, UK¹¹² Lawrence Berkeley National Laboratory, University of California at Berkeley, Berkeley, California 94720, USA¹¹³ Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California 90095, USA¹¹⁴ Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA¹¹⁵ Institute for Molecular Medicine Finland, FIMM, University of Helsinki, P.O. BOX 20, FI-00014, Helsinki, Finland¹¹⁶ Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina 27599-7160, USA¹¹⁷ Center for Human Genetic Research and Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA¹¹⁸ Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia 23298, USA¹¹⁹ Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA¹²⁰ PharmaTherapeutics Clinical Research, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, USA¹²¹ Psychiatry and Psychotherapy Clinic, University of Erlangen, 91054 Erlangen, Germany¹²² Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA¹²³ Research and Development, Bronx Veterans Affairs Medical Center, New York, New York 10468, USA¹²⁴ Institute of Molecular Genetics, Russian Academy of Sciences, Moscow 123182, Russia¹²⁵ Wellcome Trust Centre for Human Genetics, Oxford, OX3 7BN, UK¹²⁶ Department of Clinical Neurology, Medical University of Vienna, 1090 Wien, Austria¹²⁷ Lieber Institute for Brain Development, Baltimore, Maryland 21205, USA¹²⁸ Department of Medical Genetics, University Medical Centre Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands¹²⁹ Department of Psychiatry, Washington University, St. Louis, Missouri 63110, USA¹³⁰ Berkshire Healthcare NHS Foundation Trust, Bracknell RG12 1BQ, UK¹³¹ Department of Psychology, The Jockey Club Tower, 6/F, the Centennial Campus, Pokfulam Road, The University of Hong Kong, Hong Kong, China¹³² Health Research Board, Dublin 2, Ireland¹³³ Department of Clinical Medicine, University of Copenhagen, Copenhagen 2200, Denmark¹³⁴ School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Perth WA 6009, Australia¹³⁵ Computational Sciences CoE, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, USA

Author Contributions: Drs Lee and Mehta had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Lee, Wray.

Acquisition, analysis, or interpretation of data: Lee, Wray, Mehta, Tropf, Mills, Gratten, McGrath, Kendler, Bakshi, Zhu, Hemani, Magnusson, Esko, Metspalu, Snieder.

Drafting of the manuscript: Lee, Mehta, Wray, Tropf, Gratten, Kendler.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Lee, Mehta.

Obtained funding: Lee, Wray.

Administrative, technical, or material support: All authors.

Study supervision: Lee.

Conflict of Interest Disclosures: None reported.

Data Availability Statement:

This study was conducted through approved data analysis applications made to the consortia involved. For ethical and legal reasons we are not allowed to distribute them. The data of Schizophrenia Working Group of the Psychiatric Genomics Consortium can be accessed through secondary analysis proposals see <http://www.med.unc.edu/pgc/documents/documents-for-investigators#access>. The TwinsUK data are available on request by contacting the Twin Research Unit at www.twinsuk.ac.uk/data-access/ submission-procedure. The data cannot be released without assessment by a steering committee with transfer agreements as the phenotypic data can be sensitive and may in some cases lead to the identification of the twins involved in the study. These procedures have been put in place by the local ethics committee and the Wellcome Trust. The LifeLines data are available by contacting the LifeLines Research Office (LLscience@umcg.nl) (<https://www.lifelines.nl/lifelines-research/access-to-lifelines/application-process>). The data cannot be released without assessment by the LifeLines Scientific Committee with transfer agreements since the phenotypic data can be sensitive and has the potential in some cases to lead to the identification of individuals involved in the study. These procedures have been put in place by the LifeLines Scientific Board and local ethic committees. For more information see: Scholtens, S., N. Smidt, M.A. Swertz, S.J.J. Bakker, A. Dotinga, J.M. Vonk, F. Van Dijk, S.K.R. van Zon, C. Wijmenga, B.H.R. Wolffenbuttel & R. P. Stolk. (2014). Cohort Profile: LifeLines, a three-generation cohort study and biobank, *International Journal of Epidemiology*, 1-9.

¹The University of Queensland, Queensland Brain Institute, Brisbane, Queensland, Australia
²Department of Sociology/ICS, University of Groningen, The Netherlands ³Virginia Institute of Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia, USA
⁴Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA ⁵MRC Integrative Epidemiology Unit (IEU) at the University of Bristol, School of Social and Community Medicine, Bristol BS8 1TH, UK ⁶Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden ⁷Nuffield College and Department of Sociology, University of Oxford, Oxford, England ⁸Estonian Genome Center, University of Tartu, Tartu, Estonia ⁹Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands ¹⁰Queensland Centre for Mental Health Research, Wacol, Queensland, Australia ¹¹Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, Virginia, USA ¹²School of Environmental and Rural Science, The University of New England, Armidale, Australia ¹³Consortium authors and collaborators are listed at the end of the ms ¹⁴LifeLines Cohort Study, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Abstract

Importance—A recent published study of national data showed increased risk of schizophrenia (SCZ) in offspring associated with both early and delayed parental age, consistent with a U-shaped relationship. However, it remains unclear if the risk to the child is due to psychosocial factors associated with parental age, or if those at higher risk for SCZ tend to have children at an earlier or later age.

Objective—To determine if there is a genetic association between SCZ and age at first birth (AFB) using genetically informative but independently ascertained data sets.

Design, Setting, and Participants—We used genome-wide association study (GWAS) data from 18,957 SCZ cases and 22,673 controls and from 12,247 women from independent community samples not enriched for psychiatric disorders measured for AFB. SCZ genetic risk for each woman in the AFB sample was estimated using genetic effects inferred from the SCZ GWAS.

Main Outcomes and Measures—We tested if SCZ genetic risk was a significant predictor of response variables based on published polynomial functions that described the relationship between maternal age and SCZ risk in offspring in Denmark. We substituted AFB for maternal age in these functions, one of which was corrected for age of the father, and found that the fit was superior in the model without adjustment for father's age.

Results—We observed a U-shaped relationship between SCZ risk and AFB, consistent with the previously reported relationship between SCZ risk in offspring and maternal age when not adjusted for age of the father. We confirmed that SCZ risk profile score significantly predicted the response variables reflecting the published relationship between maternal age and SCZ risk in offspring from McGrath *et al.* (2014) (p-value=4E-04).

Conclusions and Relevance—It has been reported that SCZ risk associated with increased maternal age is explained by age of the father, and that *de novo* mutations that occur more

frequently in the germline of older men are the underlying causal mechanism. This explanation may need to be revised if, as suggested here, and if replicated in future studies, there is also an increased genetic risk of SCZ in older mothers.

INTRODUCTION

Parental age is a risk factor for a range of adverse mental health outcomes in children, including common psychiatric disorders such as schizophrenia (SCZ)¹⁻³. Advanced paternal age has received the most attention, with risk to children widely assumed to be explained by *de novo* mutations that occur more frequently in the germline of older men⁴⁻⁶, although there are studies questioning the *de novo* mutation hypothesis^{7,8}. There is also emerging evidence to suggest that children of both younger⁹ and older¹⁰ mothers are at increased risk of psychosis.

One recent major study is from McGrath et al. (2014)¹¹ who performed a comprehensive analysis using family data extracted from the Danish Psychiatric Central Register and reported a U-shaped relationship between maternal age and risk of SCZ in offspring. They showed that there was higher risk in children of younger and older mothers compared to those of intermediate age (25-29 years). In their second analyses that were adjusted for age of the father, which tends to be highly correlated with mother's age, increased risk of SCZ was associated with younger mothers (<25 years), but not older mothers. Conversely, children of older fathers (>29 years) were at increased risk, even after correcting for age of the mother, but children of younger fathers were not. These epidemiological findings for the association of maternal age and risk of SCZ cannot dissect cause from consequence. That is, it is unclear if risk to offspring is due to psychosocial, lifestyle or biological ageing factors associated with maternal age, or if women at higher risk for SCZ tend, on average, to have their (first) child at an earlier or later age. Here our analyses use a novel design to explore the relationship between age at motherhood and schizophrenia.

Recently developed whole genome analysis methods provide an opportunity to investigate this question in a novel way that is independent of potential confounding factors. Genomic relationships and risk profile scores on unrelated individuals derived from genome-wide single nucleotide polymorphism (SNP) data can be used to dissect the (shared) genetic architecture of complex traits¹². For instance, independently unrelated individuals can be linked through genomic information, correlating their genotype sharing with similarities in their phenotypes. Since the individuals who are compared are not related in the conventional sense, any covariance between their shared genome and their phenotype is most likely genetic, and likely free of confounding environmental effects. This novel design enables using independent genome wide association studies (GWAS) datasets to quantify the extent of genetic overlap across complex traits.

Here, we investigated the genetic relationship between SCZ and age at first birth in women (AFB) using multiple independent GWAS data sets. Specifically, we used genetic risk alleles and their effect sizes estimated from SCZ GWAS data to create a genetic risk profile score of SCZ for each woman in the AFB data set. The AFB data set comprises community samples of women, (i.e., not ascertained for psychiatric disorders) who had their age at the birth of

their first child recorded. While both SCZ and AFB are heritable traits¹³⁻¹⁵, here the genetic contribution underpinning the trait age at first motherhood is not dependent on the age of her partner. We tested if the relationship between a woman's AFB and her SCZ risk profile score matched that reported by McGrath *et al.*(2014)¹¹ between age of mothers and the incidence rate ratio (IRR) for SCZ in their children .

METHODS

Data and statistical analysis

The SCZ sample comprised 18,957 SCZ cases and 22,673 controls in a GWAS from the second phase of the Psychiatric Genomics Consortium (PGC2-SCZ)¹⁵ and the AFB sample comprised 12,247 genotyped women measured for AFB from four community cohorts (from Estonia (EGCUT), the Netherlands (Lifelines), Sweden (Swedish Twin Registry) and the UK (TwinsUK) (see eAppendix 1 in the Supplement for full details)). These community cohorts measured for AFB were not enriched for psychiatric disorders. We used genomic best linear unbiased prediction (GBLUP), implemented in the MTG software¹⁶, to estimate SNP effects in our QCed PGC2-SCZ dataset (N=41630, eTable 1 provides sample details). Briefly, SNP effects were estimated jointly within a linear mixed model that intrinsically accounts for linkage disequilibrium between SNPs. In estimating SNP effects, we fitted sex, cohort and 20 principal components obtained from the sample to control for potential confounding effects such as population stratification and potential batch effects. The SNP risk predictors were projected into the AFB samples, resulting in a GBLUP risk profile score for each individual. We repeated our analyses using standard genetic risk profile scores^{17,18}, (see eAppendix 2 in the Supplement), in which the SCZ risk scores in the women measured for AFB were estimated by summing the count of the SCZ risk alleles weighted by their effect sizes (log(odds ratio)) estimated from our QCed SCZ GWAS. A regression of phenotype on genetic risk profile score tests for association between the measures. The GBLUP risk profile score is expected to be more accurate than a standard risk profile score as the available data in the SCZ sample is used more optimally in the GBLUP linear mixed model methodology. In particular, arbitrary decisions about p-value and linkage disequilibrium clumping that are inherent in standard profile scoring are avoided.

The distribution of AFB and year of birth for each cohort is described in Table 1 and eFigures 1 and 2. In analyses for AFB, we generated two response variables using polynomial functions derived from McGrath *et al.* (2014) to describe the relationship between IRR for SCZ in offspring and maternal age (Model1 = $2.7214 + 0.0018x^2 - 0.1105x$), or maternal age adjusted for age of other parent and urbanization of place of birth (Model2 = $2.5438 + 0.0012x^2 + 0.0889x$). eFigure 3 and eFigure 4 show how we derived the polynomial functions. In generating the Model1 and Model2 values for each individual, AFB was used as the x variable in the equations. In analyses, we used the residuals of the Model1 or Model2 values after regression on covariates such as age at interview, 20 ancestry principal components and cohort. We did not include year of birth as a covariate because its negative value was highly correlated with age at interview (>0.9). The fitted residuals were regressed against the risk profile scores and we report the proportion of variance (R^2) attributable to the polygenic score. The p-value results from the test of the hypothesis $R^2 =$

0. The purpose of these analyses was to test if the SCZ polygenic risk values are a better fit to the phenotypic risk values predicted by Model 1 or Model 2. A smaller p-value for Model1 would imply a better fit to the AFB data compared to Model2 for which the linear and quadratic coefficients were derived from models that adjusted for the age of partner. Analyses were performed for the entire AFB sample and also for subsets of women stratified by mean AFB (26 years) into younger AFB (<26) and older AFB (≥ 26).

RESULTS

We sought to provide insight to the relationship between maternal age and SCZ by exploring the genetic overlap between SCZ risk in women measured for AFB. We observed a U-shaped relationship between AFB and SCZ risk profile scores derived using GBLUP (Figure 1), consistent with the relationship reported by McGrath and colleagues (2014) between SCZ risk in offspring and maternal age not adjusted for father's age. The mean risk profile score from GBLUP analysis was significantly higher in women with early AFB (i.e. < 20) than in women with intermediate AFB (p-value=9E-03 for 25 AFB<30 and p-value=1E-02 for 30 AFB<35) (eTable 2). The results from standard profile score were very similar to those from GBLUP but showed weaker signals (eFigure 5).

We further investigated if SCZ genetic risk profiles significantly predicted the Model1 and/or Model2 response variables, which are the phenotypic predictors of SCZ risk derived from the results reported by McGrath et al (2014) (Table 2). We initially focused on a subsample of women aged ≥ 45 years at recruitment (N=10836), to avoid any potential bias owing to the inclusion of women who were childless at recruitment but still of childbearing age. In analyses of the full range of AFB in this sample, the Model1 and Model2 response variables were strongly predicted by GBLUP-derived SCZ risk profile scores (p-value=4E-04 and 5E-03 for Model1 and Model2, respectively) (Table 2). The smaller p-value for Model1 implies a better fit to the AFB data compared to the Model2, which is consistent with the suggestion that adjusting for paternal age removes a true association between maternal age and IRR for SCZ. When restricting the analysis to younger mothers whose AFB was less than the average (AFB<26), the p-value was 6E-04 and 5E-04 for Model1 and Model2, respectively (Table 2). On the other hand, assessing only older mothers (AFB ≥ 26), GBLUP profile score weakly predicted Model1 (p-value=1E-02) but not Model2 (p-value= 2E-01) (Table 2). We repeated the analyses using the total sample of 12247 women and found almost identical results (eTable 3), suggesting very little if any bias arising from the inclusion of an additional 1411 women aged <45 years at recruitment. Again, analyses based on the profile score approach gave similar but weaker significance than GBLUP (eTable 4).

In our primary analyses we excluded women without children, since the appropriate way to include such women in our analyses is difficult to determine. Delayed AFB and childlessness might have a common genetic predisposition or might be on distinct dimensions of liability. To explore this, we repeated analyses including women having no children, whose age at recruitment was 45 years or over. In this analysis, we assigned women having no children an AFB=45 years, which has been reported as the end of reproductive age¹⁹. Both response variables were predicted in analyses across the full range

of AFB, but the significance of the prediction was considerably decreased, and neither response variable was predicted in analyses of women with AFB ≥ 26 (eTable 5). These results must be interpreted with caution since there could be many reasons why women have no children, the most common being infertility which is likely to be genetically independent of AFB amongst those able to conceive.

In addition to analyses of the total AFB sample, we examined the relationship between SCZ risk profile scores from GBLUP and the Model1 and Model2 response variable in each cohort (eTable 6), acknowledging that due to smaller sample size, the power to detect a relationship was substantially reduced. For Estonia, risk profile scores were not significantly associated with AFB (see Discussion). However, a significant association remained in the other cohorts for at least one response variable. The prediction for LifeLines was significant for Model1 when using the whole range of AFB or AFB < 26 years. For the Swedish Twin Registry (STR), it was significant only for Model1 in analyses of women with AFB ≥ 26 years. For the UK, both response variables were predicted in analyses of the full range of AFB and AFB < 26, but not in analyses of women with AFB ≥ 26 (eTable 6). Due to smaller sample size, the U-shaped relationship observed between SCZ risk and AFB was less apparent in each cohort (eFigure 6).

We stratified the AFB sample into birth cohorts born before or after 1945, a demarcation based on the Second Demographic Transition that is linked in the literature to postponement of AFB²⁰. For individuals born after 1945, SCZ risk profile scores from GBLUP significantly predicted AFB for the entire sample and the younger AFB group, but not for the older AFB group (eTable 7). For individuals born before 1945, SCZ risk profile scores from GBLUP did not significantly predict AFB (eTable 7).

DISCUSSION

Maternal age is a risk factor for a number of adverse mental health outcomes, including common psychiatric disorders such as schizophrenia^{21,22;34}. In a recent study, McGrath et al. (2014)¹¹ reported a U-shaped relationship between maternal age and risk of SCZ in children, although in analyses corrected for age of the other parent only children of younger mothers were at increased risk. Their study implied that risk of SCZ in children of older mothers was attributable to the father's age, consistent with the hypothesis of risk arising from paternal age-related *de novo* mutations and the presence of a strong correlation between maternal and paternal age. However, since a larger proportion of older men have younger partners than is the case for older women, there is a possibility that correcting for age of spouse may remove a true effect due to advanced maternal age. In other words, the well-known problem of collinearity²³⁻²⁵, which can lead to biased estimates for explanatory variables that are adjusted for a correlated variable (e.g. maternal age adjusted for paternal age) may result in an underestimate of the risk due to older maternal age in analyses such as that reported by McGrath et al (2014). Our study uses a novel experimental design that is free of the effects of partner's age, and therefore, there is no concern about such a collinearity problem in our analyses.

Maternal age is a proxy for factors other than parental age, including *de novo* chromosomal abnormalities, and psychosocial factors related to socioeconomic status and educational attainment, both of which are associated with risk of SCZ. Conversely, relatives of individuals affected with SCZ tend to have relatively poor social interactions²⁶, which may increase the time taken to find a mate and thereby delay age at first birth. SCZ risk may also predispose to risk taking and impulsive behaviour, which is associated with early pregnancy and childbirth in females²⁷⁻²⁹. Consequently, risk of SCZ in offspring due to maternal AFB may be influenced by shared genetic factors between mothers and offspring, as has been suggested for paternal AFB^{7,8}.

In this study, we investigated the genetic overlap between SCZ and AFB using a novel experimental design based on genomic data that enables genetic effects to be disentangled from other confounding factors. This is achieved through independently collected SCZ and AFB data sets that are genetically informative. The AFB data are collected from community samples with no known enrichment for psychiatric disorders. In particular, we sought to determine if response variables based on the relationships reported by McGrath et al. (2014) between maternal age and SCZ risk in children (Model1 and Model2) could be predicted by SCZ risk profile scores in our independent data. We found that SCZ risk profile scores predicted both Model1 and Model2, implying that polygenic variation for SCZ contributes to the relationships reported by McGrath et al. (2014) between maternal age and risk of SCZ.

Our results were stronger for the U-shaped Model1 response variable (based on unadjusted IRR) than Model2 (in which IRR was adjusted for paternal age and urbanization of place of birth), suggesting that polygenic variation contributes to risk of SCZ associated with both early and delayed maternal AFB. In analyses stratified by mean AFB, evidence for genetic overlap between SCZ and AFB was strongest in women with early AFB (AFB<26). In analyses of women with delayed AFB (AFB ≥ 26 years), we observed an association with SCZ risk profile score, but only for the Model1 response based on unadjusted IRR. Given our methodology explores the relationship between AFB genetic risk to SCZ in a way that is independent of the correlation between the ages of the parents, our analyses suggest that risk of SCZ in children of older mothers is not solely attributable to factors associated with advanced paternal age.

A caveat of our findings is that the genetic association between risk of SCZ and delayed AFB were only marginally significant given the number of analyses performed, perhaps reflecting smaller sample size and correspondingly larger standard errors for women with delayed AFB, and so require replication in a larger sample. Provided this finding is confirmed in a future study, it has important implications because it implies that the risk of SCZ associated with increased age in mothers is not entirely due to the father's age.

Although we demonstrate that SCZ genetic risk can be disentangled from psychosocial, lifestyle and/or biological ageing factors in assessing the relationship between SCZ risk and AFB, we cannot explicitly determine mechanism and it is possible that subtle correlations between genetic and non-genetic factors might influence this relationship. Several mechanisms such as correlation of SCZ risk with socioeconomic status and other

environmental and biological factors might also influence the genetic relationship between SCZ and AFB. For instance, SCZ risk could predispose to impulsive behaviour²⁹ and substance use²⁷ that are associated with early pregnancy and childbirth²⁸. On the other hand, poor social competence in SCZ might delay the time to meet a partner and/or have offspring, causing delayed AFB. Other plausible mechanisms such as low IQ and poor educational attainment that are strong risk factors for both SCZ³⁰ and early pregnancy²¹ need to be explored although including genetic profile score for educational attainment as a covariate had little impact on our results (eTable 8). Assessing these factors is beyond the scope of this study. Future research including social science measures and information on the non-genetic factors will facilitate a deeper understanding of causal pathways underlying the association between SCZ and AFB.

The analyses of McGrath et al (2014) explored the relationship between parental age and a broad range of psychiatric disorders. Here, we have only considered genetic risk for schizophrenia because sample size, and hence power to estimate risk allele effect sizes, is greatest. For example, for SCZ 108 independent risk loci have been identified as genome-wide significant¹⁵, compared to only 3 for bipolar disorder (PGC-BPD, 2011)³¹. As GWAS sample sizes for other psychiatric disorders increase, then replication of our analyses based on these disorders will be possible.

In summary, this study provides evidence for a significant overlap between genetic factors associated with risk of SCZ and genetic factors associated with AFB. This is the first study to explore a genetic relationship between SCZ and AFB using independent unrelated samples based on genomic data. We conclude that women with high genetic predisposition to SCZ tend to have their first child at an early or later age.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research is supported by the Australian National Health and Medical Research Council (grants 613602, 1047956, 1078901, 1080157, 1087889, 1067795) and the Australian Research Council (DE130100614). The research leading to these results received funding from the European Research Council via an ERC Consolidator Grant SOCIOGENOME (615603 awarded to M. Mills, see www.sociogenome.com). Felix C. Tropp additionally received funding from sciencestarter.de for the research visit to the University of Queensland. The TwinsUK study was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007–2013).

EGCUT received targeted financing from Estonian Research Council grant IUT20-60, Center of Excellence in Genomics (EXCEGEN) and University of Tartu (SPIGVARENG). We acknowledge EGCUT technical personnel, especially Mr V. Soo and S. Smit. Data analyses were carried out in part in the High Performance Computing Center of University of Tartu.

TwinsUK. The study was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013). The study also receives support from the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. SNP Genotyping was performed by The Wellcome Trust Sanger Institute and National Eye Institute via NIH/CIDR

The SNP&SEQ Technology Platform at the Uppsala University are acknowledged for performing genotyping and for excellent technical assistance. The Swedish Twin Registry is supported by Karolinska Institutet

Primary analyses of the Schizophrenia Working Group of the Psychiatric Genomics Consortium data were conducted on the Genetic Cluster Computer (<http://www.geneticcluster.org>) hosted by SURFsara and financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation and the VU University Amsterdam.

The acknowledgements for Schizophrenia Working Group of the Psychiatric Genomics Consortium data are listed in reference #15 (and repeated in the Supplementary Material).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References

1. Bassett AS, Bury A, Hodgkinson KA, Honer WG. Reproductive fitness in familial schizophrenia. *Schizophr Res.* 1996; 21(3):151–160. [PubMed: 8885043]
2. MacCabe JH, Koupil I, Leon DA. Lifetime reproductive output over two generations in patients with psychosis and their unaffected siblings: the Uppsala 1915–1929 Birth Cohort Multigenerational Study. *Psychological medicine.* 2009; 39(10):1667–1676. [PubMed: 19265569]
3. McGrath JJ, Hearle J, Jenner L, Plant K, Drummond A, Barkla JM. The fertility and fecundity of patients with psychoses. *Acta psychiatrica Scandinavica.* 1999; 99(6):441–446. [PubMed: 10408266]
4. D’Onofrio BM, Rickert ME, Frans E, et al. Paternal age at childbearing and offspring psychiatric and academic morbidity. *JAMA psychiatry.* 2014; 71(4):432–438. [PubMed: 24577047]
5. Das M, Al-Hathal N, San-Gabriel M, et al. High prevalence of isolated sperm DNA damage in infertile men with advanced paternal age. *Journal of assisted reproduction and genetics.* 2013; 30(6): 843–848. [PubMed: 23722935]
6. Kong A, Frigge ML, Masson G, et al. Rate of de novo mutations and the importance of father’s age to disease risk. *Nature.* 2012; 488(7412):471–475. [PubMed: 22914163]
7. Jaffe AE, Eaton WW, Straub RE, Marenco S, Weinberger DR. Paternal age, de novo mutations and schizophrenia. *Mol Psychiatry.* 2014; 19(3):274–275. [PubMed: 23752248]
8. Petersen L, Mortensen PB, Pedersen CB. Paternal age at birth of first child and risk of schizophrenia. *Am J Psychiatry.* 2011; 168(1):82–88. [PubMed: 20952457]
9. Eaton WW, Mortensen PB, Frydenberg M. Obstetric factors, urbanization and psychosis. *Schizophr Res.* 2000; 43(2–3):117–123. [PubMed: 10858630]
10. Hultman CM, Ohman A, Cnattingius S, Wieselgren IM, Lindstrom LH. Prenatal and neonatal risk factors for schizophrenia. *The British journal of psychiatry : the journal of mental science.* 1997; 170:128–133. [PubMed: 9093500]
11. McGrath JJ, Petersen L, Agerbo E, Mors O, Mortensen PB, Pedersen CB. A comprehensive assessment of parental age and psychiatric disorders. *JAMA psychiatry.* 2014; 71(3):301–309. [PubMed: 24452535]
12. Lee SH, Ripke S, Neale BM, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat Genet.* 2013; 45(9):984–994. [PubMed: 23933821]
13. Tropf FC, Stulp G, Barban N, et al. Human fertility, molecular genetics, and natural selection in modern societies. *PLoS One.* 2015; 10(6):e0126821. [PubMed: 26039877]
14. Mills M, Tropf F. The biodemography of fertility: A review and future research frontiers. *Kölner Zeitschrift für Soziologie und Sozialpsychologie.* 2015
15. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature.* 2014; 511(7510):421–427. [PubMed: 25056061]
16. Maier R, Moser G, Chen GB, et al. Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. *Am J Hum Genet.* 2015; 96(2):283–294. [PubMed: 25640677]
17. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature.* 2009; 460(7256):748–752. [PubMed: 19571811]

18. Wray NR, Lee SH, Mehta D, Vinkhuyzen AAE, Dudbridge F, Middeldorp CM. Research Review: Polygenic methods and their application to psychiatric traits. *Journal of Child Psychology and Psychiatry*. 2014; 55(10):1068–1087. [PubMed: 25132410]
19. Leridon H. A new estimate of permanent sterility by age: sterility defined as the inability to conceive. *Population studies*. 2008; 62(1):15–24. [PubMed: 18278670]
20. Lesthaeghe R. The unfolding story of the second demographic transition. *Population and development review*. 2010; 36(2):211–251. [PubMed: 20734551]
21. Fergusson DM, Woodward LJ. Maternal age and educational and psychosocial outcomes in early adulthood. *Journal of child psychology and psychiatry, and allied disciplines*. 1999; 40(3):479–489.
22. Moore GS, Kneitel AW, Walker CK, Gilbert WM, Xing G. Autism risk in small- and large-for-gestational-age infants. *American journal of obstetrics and gynecology*. 2012; 206(4):314, e311–319. [PubMed: 22464070]
23. Tu YK, Kellett M, Clerehugh V, Gilthorpe MS. Problems of correlations between explanatory variables in multiple regression analyses in the dental literature. *British dental journal*. 2005; 199(7):457–461. [PubMed: 16215581]
24. Belsley D. A Guide to using the collinearity diagnostics. *Computer Science in Economics and Management*. 1991; 4(1):33–50.
25. Farrar DE, Glauber RR. Multicollinearity in Regression Analysis: The Problem Revisited. *The Review of Economics and Statistics*. 49:92–107.
26. Bellack AS, Morrison RL, Wixted JT, Mueser KT. An analysis of social competence in schizophrenia. *The British journal of psychiatry : the journal of mental science*. 1990; 156:809–818. [PubMed: 2207511]
27. Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS. The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. *Psychological medicine*. 2015; 45(2):407–414. [PubMed: 24990397]
28. Salas-Wright CP, Vaughn MG, Ugalde J, Todic J. Substance use and teen pregnancy in the United States: evidence from the NSDUH 2002-2012. *Addictive behaviors*. 2015; 45:218–225. [PubMed: 25706068]
29. Reddy LF, Lee J, Davis MC, et al. Impulsivity and risk taking in bipolar disorder and schizophrenia. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2014; 39(2):456–463. [PubMed: 23963117]
30. Morra LF, Gold JM, Sullivan SK, Strauss GP. Predictors of neuropsychological effort test performance in schizophrenia. *Schizophrenia research*. 2015; 162(1–3):205–210. [PubMed: 25583248]
31. Sklar P, Ripke S, Scott LJ, et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nature Genetics*. 2011; 43(10):977–983. [PubMed: 21926972]




Figure 1. Mean SCZ profile scores from GBLUP in community samples of women (no ascertainment based on psychiatric disorders) grouped by age at birth of their first child. The error bars are SE.

Table 1

The number of sample size and distribution of AFB across four cohorts.

Cohort	Sample size	Mean Age (interview)	Range Age	Mean AFB	Range AFB
EGCUT	1660	67.3	45–101	24.8	15–46
LifeLines	5344	53.1	27–93	26.7	16–43
STR	3262	58.2	45–86	25.1	14–52
TwinsUK	1981	55.4	25–86	25.7	14–44

Abbreviation: AFB, maternal age at first birth. EGCUT, the Estonian Genome Center Biobank, University of Tartu. STR, the Swedish Twin Registry.

Table 2The coefficient of determination (R^2) and p-value^a

Data set	Response variable	R^2	p-value ^d
Full range of AFB (N=10836)	Model1 ^b	1.1E-03	4.1E-04
	Model2 ^c	6.4e-04	5.0E-03
AFB < 26 (N=5827)	Model1	1.8E-03	6.2E-04
	Model2	1.9E-03	5.1E-04
AFB >= 26 (N=5009)	Model1	1.0E-03	1.4E-02
	Model2	6.5E-05	2.5E-01

Abbreviation: GBLUP, genomic best linear unbiased linear prediction. AFB age at birth in women.

^aIn the analyses, either the Model1 or Model2 variables was used as the dependent variables in regression on GBLUP risk profile score using only women aged 45 years or over at recruitment. AFB was used as the x variable in this study. The analysed Model1 and Model2 variables were the residuals from a regression fitting potential confounders as covariates.

^bModel1: Polynomial function derived from incidence ratio for schizophrenia by maternal age (x) presented in McGrath et al (2014) (Model1 = $2.7214 + 0.0018x^2 - 0.1105x$).

^cModel2: polynomial function derived from incidence ratio for schizophrenia by maternal age adjusted for age of other parent and urbanization of place of birth (x) presented in McGrath et al (2014) (Model2 = $2.5438 + 0.0012x^2 + 0.0889x$).

Including genetic profile score for educational attainment as a covariate had little impact on these results (eTable 8).

^dP-value for H₀: $R^2 = 0$